R B van Leeuwen1, T D Bruintjes. 1. Department of Neurology, Gelre Hospital Apeldoorn, Apeldoorn, The Netherlands. r.b.van.leeuwen@gelre.nl
Abstract
OBJECTIVE: To evaluate the natural course of recurrent vestibulopathy. STUDY DESIGN: Retrospective analysis. PATIENTS: One hundred and five adult patients with attacks of vertigo without auditory or neurological symptoms. METHODS: A structured interview was conducted over the telephone, 12 to 62 months after the patient's first visit to the out-patient department. RESULTS: Two-thirds of patients experienced spontaneous resolution of vertigo, while one-third continued to have symptoms. The diagnosis was subsequently changed to migraine in 2 per cent of patients and to Ménière's disease in 1 per cent. CONCLUSION: The prognosis for patients with recurrent vestibulopathy is good. In a few cases, the diagnosis is provisional and will be subsequently changed to migraine or Ménière's disease.
OBJECTIVE: To evaluate the natural course of recurrent vestibulopathy. STUDY DESIGN: Retrospective analysis. PATIENTS: One hundred and five adult patients with attacks of vertigo without auditory or neurological symptoms. METHODS: A structured interview was conducted over the telephone, 12 to 62 months after the patient's first visit to the out-patient department. RESULTS: Two-thirds of patients experienced spontaneous resolution of vertigo, while one-third continued to have symptoms. The diagnosis was subsequently changed to migraine in 2 per cent of patients and to Ménière's disease in 1 per cent. CONCLUSION: The prognosis for patients with recurrent vestibulopathy is good. In a few cases, the diagnosis is provisional and will be subsequently changed to migraine or Ménière's disease.
Authors: B Loader; I Linauer; S Korkesch; I Krammer-Effenberger; V Zielinski; N Schibany; A Kaider; E Vyskocil; D Tscholakoff; P Franz Journal: Acta Otorhinolaryngol Ital Date: 2016-10 Impact factor: 2.124
Authors: Julia Dlugaiczyk; Thomas Lempert; Jose Antonio Lopez-Escamez; Roberto Teggi; Michael von Brevern; Alexandre Bisdorff Journal: Front Neurol Date: 2021-06-17 Impact factor: 4.003